Sarepta Therapeutics, Inc. (LON:0L35)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.38B -84.7% |
| Revenue (ttm) | 1.80B +47.1% |
| Net Income | -201.99M |
| EPS | -2.06 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,138 |
| Average Volume | 10,718 |
| Open | 17.96 |
| Previous Close | 17.80 |
| Day's Range | 17.29 - 18.29 |
| 52-Week Range | 10.49 - 110.97 |
| Beta | 0.39 |
| RSI | 35.12 |
| Earnings Date | Feb 25, 2026 |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]
News
Sarepta (SRPT) Receives Green Light for Huntington's Disease Trial
Sarepta (SRPT) Receives Green Light for Huntington's Disease Trial
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medicines and Med...
Sarepta (SRPT): Analyst Reiterates Sell Rating Due to Data Concerns
Sarepta (SRPT): Analyst Reiterates Sell Rating Due to Data Concerns
Sarepta Therapeutics (SRPT): Analyst Reiterates Sell Rating Today | SRPT Stock News
Sarepta Therapeutics (SRPT): Analyst Reiterates Sell Rating Today | SRPT Stock News
Sarepta Therapeutics Inc to Discuss 3-Year Topline Functional Results Transcript
Sarepta Therapeutics Inc to Discuss 3-Year Topline Functional Results Transcript
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript
Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy January 26, 2026...
Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones gaining over 100 points on Monday. Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) rose sharply during Monday's session after the company released toplin...
Sarepta (SRPT) Shares Surge Over 14% Amid Positive Momentum
Sarepta (SRPT) Shares Surge Over 14% Amid Positive Momentum
Sarepta's ELEVIDYS Slows Disease Progression In Ambulatory Duchenne Patients In EMBARK Study
(RTTNews) - Sarepta Therapeutics Inc. (SRPT), on Monday, announced positive topline three-year results from its EMBARK study, showing that ELEVIDYS significantly slowed disease progression across key ...
Sarepta Therapeutics (SRPT) Shares Surge on Positive Elevidys Results
Sarepta Therapeutics (SRPT) Shares Surge on Positive Elevidys Results
Sarepta (SRPT) Reports Positive Three-Year Data for Duchenne Gene Therapy
Sarepta (SRPT) Reports Positive Three-Year Data for Duchenne Gene Therapy
Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys
Sarepta reports positive, statistically significant results in a study evaluating the efficacy of its blockbuster gene therapy.
Sarepta (SRPT) Shares Climb on Positive Phase 3 Study Results
Sarepta (SRPT) Shares Climb on Positive Phase 3 Study Results
Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows
Sarepta Therapeutics' gene therapy for a progressive muscle‑wasting disorder showed sustained benefit in patients' ability to control and coordinate movement, according to three‑year data from a late‑...
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline three-year functional results ...
Stock Market Today: Dow Jones, S&P 500 Futures Slip As Investors Brace For Mega-Cap Earnings—Brand Engagement, Nucor In Focus
U.S. stock futures dropped on Monday following Friday’s mixed close. Futures of major benchmark indices were lower. This week, investors are eyeing earnings from UnitedHealth Group Inc. (NYSE: UNH), ...
Sarepta Therapeutics (SRPT) Surges 10% on Upcoming EMBARK Study Results
Sarepta Therapeutics (SRPT) Surges 10% on Upcoming EMBARK Study Results
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Easte...
Wedbush Raises Price Target for Sarepta Therapeutics (SRPT) to $34 | SRPT Stock News
Wedbush Raises Price Target for Sarepta Therapeutics (SRPT) to $34 | SRPT Stock News
2 Beaten-Down Stocks That Could Sink Even More in 2026
Sarepta Therapeutics' drug safety issues are overshadowing its innovative platform. Teladoc Health's financial results continue to worsen, and the stock looks unlikely to recover.
Sarepta Therapeutics: Is Elevidys A Bust?
Sarepta Therapeutics remains highly volatile as ELEVIDYS sales drive sentiment, with Q4 revenue missing expectations and safety concerns lingering. Despite fading ELEVIDYS sales, SRPT management reite...
Sarepta (SRPT) Faces Challenges with Elevidys Sales Performance
Sarepta (SRPT) Faces Challenges with Elevidys Sales Performance
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Sarepta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Sarepta Therapeutics Inc at JPMorgan Healthcare Conference Transcript